Ida Vänttinen

5PUBLICATIONS
42CO-AUTHORS
Gene and molecular therapyMolecular targetsPredictive and prognostic markersCharacterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 01, 2026
Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

|Jan 14, 2026
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.

Ida Vänttinen, Joseph Saad, Tanja Ruokoranta

|May 12, 2025
A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.

Yingjia Chen, Liye He, Aleksandr Ianevski

|Oct 02, 2024
Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.

Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta

|Apr 01, 2024
Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window.

Tero Satomaa, Henna Pynnönen, Olli Aitio

Pageof 1

Frequent Collaborators

4 joint publications

Tanja Ruokoranta

4 joint publications

Mika Kontro

4 joint publications

Caroline A Heckman

4 joint publications

Heikki Kuusanmäki